A number of clinical and preclinical programs are in development featuring our tetravalent bispecific ICE® (innate cell engager) molecules based on the ROCK® (Redirected Optimized Cell Killing) platform, and have already shown a favorable safety profile and promising signs of therapeutic efficacy.

AFM13 is a first-in-class ICE® molecule that has the potential to deliver clinically meaningful benefits to patients with CD30+ lymphomas.1

AFM24 is an EGFR-binding ICE® molecule that kills EGFR-expressing tumors, and through ADCC and ADCP, holds promise to treat all patient subtypes with a more acceptable safety profile compared with current advanced treatments, while remaining immune to the challenge of resistance.2

Expanding our pipeline are AFM28, Roivant-partnered AFM32, a Genentech-partnered ICE® molecule, and several ICE® + NK-cell combinations.

Innate Cell Engagers

Pre-Clinical
Phase 1
Phase 2
Additional Information
Disease Target CD30

AFM13-202 MONOTHERAPY

Peripheral T cell lymphoma
Phase 2b

AFM13-203 + ADOPTIVE NK CELLS

CD30-positive lymphoma
Pre-Clinical

AFM13-104 + ADOPTIVE NK CELLS

CD30-positive lymphoma
Phase 1/2a

AFM13-103 + ANTI-PD-1

Hodgkin lymphoma (post BV)
Phase 1b
Disease Target EGFR

AFM24-101 MONOTHERAPY

Multiple EGFR+ solid tumors
Phase 1/2a

AFM24-102 + ANTI-PD-L1

Multiple EGFR+ solid tumors
Phase 1/2a

AFM24-103 + ADOPTIVE NK CELLS

Multiple EGFR+ solid tumors
Phase 1/2a
Disease Target CD123

AFM28-101 MONOTHERAPY

Acute Myeloid Leukemia (AML)
Phase 1

AFM28 + ADOPTIVE NK CELLS

Acute Myeloid Leukemia (AML)
Pre-Clinical
Disease Target FRα

AFVT-2101 (AFM32) - AFFIVANT

Solid tumors
Pre-Clinical
Disease Target Undisclosed

Novel ICE® - GENENTECH

Multiple indications (not disclosed)
Pre-Clinical
Disease Target Undisclosed

Novel ICE®

Multiple indications (not disclosed)
Pre-Clinical
BV = brentuximab vedotin
CD = cluster of differentation
EGFR = epidermal growth factor receptor
FRα = Folate receptor alpha
ICE® = innate cell engager
IND = investigational new drug
NK = natural killer
PD-1 = programmed death protein1
PD-L1 = programmed death ligand 1
Affimed programs
Partnered programs
List is not exhaustive

Our clinical trials

Selected posters and publications


Hematological Malignancies

  • Bartlett et al., ASH 2018: A Phase 1 Study Investigating the Combination of AFM13 and the Monoclonal Anti-PD-1 Antibody Pembrolizumab in Patients with Relapsed/Refractory Hodgkin Lymphoma after Brentuximab Vedotin Failure: Updated Safety and Efficacy Data. View poster
  • Bartlett et al., Blood. A phase 1b study of AFM13 in combination with pembrolizumab in patients with relapsed or refractory Hodgkin lymphoma. Please see: Blood. 2020;136:2401-2409.
  • Kerbauy et al., Clin Cancer Res. Combining AFM13, a Bispecific CD30/CD16 Antibody, with Cytokine-Activated Blood and Cord Blood-Derived NK Cells Facilitates CAR-like Responses Against CD30+ Malignancies. Please see: Clin Cancer Res. 2021;27:3744-3756.
  • Sawas et al., 15-ICML 2019: Clinical and Biological Evaluation of the Novel CD30/CD16A Tetravalent Bispecific Antibody (AFM13) in Relapsed or Refractory CD30-Positive Lymphoma with Cutaneous Presentation: A Biomarker Phase Ib/IIa Study (NCT03192202). View poster
  • Oral Presentation: Ansell et al., ICML 2019: Final Results from a Phase 1b Dose Escalation Study to Assess the Safety of AFM13 in Combination with Pembrolizumab in Patients with Relapsed or Refractory Classical Hodgkin Lymphoma (AFM13-103). View poster
  • Marin et al., ASH 2018: The CD30/CD16A bispecific innate immune cell engager AFM13 elicits heterogeneous single-cell NK cell responses and effectively triggers memory like (ML) NK cells. View poster


Solid Tumors

  • Wingert et al., MAbs. Preclinical evaluation of AFM24, a novel CD16A-specific innate immune cell engager targeting EGFR-positive tumors. Please see: MAbs. 2021;13:1950264.
  • Pahl et al., AACR 2021: AFM24 is a novel, highly potent, tetravalent bispecific EGFR/CD16A-targeting Innate Cell Engager (ICE®) designed for the treatment of EGFR-positive malignancies. View poster
  • Reusch et al., AACR 2020: AFM24, a bispecific EGFR/CD16A Innate Cell Engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies. View poster
  • Kluge et al., AACR 2018: Preclinical Characterization of the Bispecific EGFR/CD16A Innate Immune Cell Engager AFM24 for the Treatment of EGFR-Expressing Solid Tumors. View poster


ICE® Molecules: Mechanism of Action

  • Wingert et al., ASH 2018: CD16A-Specific Tetravalent Bispecific Immuno-Engagers Potently Induce Antibody-Dependent Cellular Phagocytosis (ADCP) by Macrophages. View poster


ROCK® Platform

  • Ellwanger et al., MAbs. Redirected optimized cell killing (ROCK®): A highly versatile multispecific fit-for-purpose antibody platform for engaging innate immunity. Please see: MAbs. 2019;11:899-918.


See all Publications and Posters

ADCC=antibody-dependent cellular cytotoxicity; ADCP=antibody-dependent cellular phagocytosis; EGFR=epidermal growth factor receptor; IND=investigational new drug; NK=natural killer.

References: 1. Rothe A, Sasse S, Topp MS, et al. A phase 1 study of the bispecific anti-CD30/CD16A antibody construct AFM13 in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2015;125(26):4024-4031. 2. Reusch U, Damrat M, Wingert S, et al. AFM24, a bispecific EGFR/CD16A innate cell engager with the potential to overcome resistance to current targeted treatments for EGFR-positive malignancies. Poster presented at: American Association for Cancer Research (AACR) Annual Meeting; June 22-24, 2020; Virtual. Poster 5659.